+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute Otitis Media Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 140 Pages
  • June 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5617163
UP TO OFF until Dec 31st 2023
The Acute Otitis Media Treatment Market is expected to grow at the registered CAGR of 5.5% during the forecast period, 2022-2027.

The COVID-19 outbreak impacted every aspect of the healthcare industry, including the market for acute otitis media treatment, as there are significant disruptions to businesses and economic activities worldwide. According to the study titled "Otitis media in coronavirus disease 2019: a case series" published in The Journal of Laryngology and Otology in January 2021, otitis media should be considered a manifestation or associated symptom of coronavirus disease. Thus rising in the otitis media population the demand for drugs is expected to increase during the COVID-19 pandemic. However, according to the study titled "Otitis Media Practice During the COVID-19 Pandemic " in the Frontier in the Celluar and Infections Microbiology in January 2022, to avoid infection, otologic procedures were divided into urgent and elective categories. Urgent operations should be performed, while all other operations should be postponed, depending on the pathology and the patient's preference.

The primary factor driving the global acute otitis media treatment market is the rising prevalence of ear infections. The launch of novel drugs for the treatment of acute otitis media by leading pharmaceutical companies will drive the acute otitis media treatment market forward. According to the article published in the European Journal of Public Health In August 2020, titled as "Prevalence of acute otitis media in children younger than four years" acute otitis media (AOM) is one of the most common childhood diseases, affecting roughly half of all children.​Thus, rising prevalence of acute otitis media expected to rise in demand of its treatment anticipated to drive the market growth.

The introduction of new products for the treatment of acute otitis media by key players is expected to create a favourable environment for market growth in the near future. In August 2020, Sandoz Inc. introduced Ciprofloxacin 0.3% + Dexamethasone 0.1% otic suspension 7.5mL ear drops in the US market for the treatment of middle ear and outer ear canal bacterial infections. Thus, all aforementioned factors expected to boost the market over the forecast period. However, stringent guidelines for approval of the drug for the acute otitis media treatment among the children restraint the market over the forecast period.

Key Market Trends

Antibiotics Segment is Expected to Hold Significant Market Share Over the Forecast Period

If antibiotics are needed, amoxicillin is the drug of choice, given in three divided doses of 45 to 60 mg/kg per day; if a twice-daily dosing regimen is used, higher total daily doses of 75 to 90 mg/kg per day are required. If there is concurrent purulent conjunctivitis, a history of amoxicillin treatment within the previous 30 days, relapse of a recent infection, or nonresponse to amoxicillin, amoxicillin-clavulanate should be considered. Other regimens such as macrolides or clindamycin can be used but have limited efficacy.

Acute otitis media (AOM) is a viral (such as respiratory syncytial virus, rhinovirus, influenza viruses, and adenoviruses) or bacterial (such as Streptococcus pneumoniae, nontypeable Haemophilus influenzae, and Moraxella catarrhalis) infection of the middle ear. Thus, the effectiveness of antibiotics in such infections is anticipated to drive the segment growth.

According to the study titled "From Evidence to Clinical Guidelines in Antibiotic Treatment in Acute Otitis Media in Children" published in the Antibiotics Basel in January 2021, effective therapies AOM causing pathogens include clindamycin, chloramphenicol, and metronidazole in combination with a macrolide, or the combinations of amoxicillin/clavulanate or piperacillin/tazobactam. Thus, antibiotics is one of the important treatment option in AOM anticipated to drive the demand for it thereby boost the segment.

Therefore, due to these factors mentioned above, the antibiotics segment is expected to grow and occupy a major share in the antibiotics market over the forecast period of the study.

North America Dominates the Market and Expected to do Same in the Forecast Period.

The acute otitis media treatment market holds the largest share in the North American region due to the high prevalence of otitis media infection. According to an article published by the National Institute on Deafness and Other Communication Disorders in March 2021, five out of six children in the country experience ear infection by 3 years of age. Thus, the high incidence rate of ear infection in the country is projected to drive the market. According to the report titled “Acute Otitis Media”, published in March 2021, otitis media is most commonly seen between 6 and 24 months. Approximately 80% of all children experience a case of otitis media during their lifetime, and between 80% and 90% of all children will have otitis media with an effusion before school age.

In addition, the launch of new medicines for the treatment of ear infections in the country may drive the market. In June 2020, ALK has sighed of an exclusive agreement with Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, for the co-promotion of OTIPRIO (ciprofloxacin otic suspension) for acute otitis externa (AOE) in the United States in patients six months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.​

In August 2021, the United States had nearly 20 million estimated cases of acute middle ear infections, and the annual cost associated with this condition is estimated to exceed USD 4 billion. Thus, such product launches may positively impact the market's growth over the forecast period. Thus, such factors are expected to significantly boost the United States ear infection treatment market during the forecast period.​

Competitive Landscape

The majority of key players involved in the research and manufacturing of ear infection treatment are established in developed countries. Market leaders with more funds for research and a better distribution system have established their position in the market. The market studied is moderately competitive with several international as well as regional players. In terms of market share, the acute otitis media treatment market is dominated by major market players such as Pfizer, Inc., Eli Lilly and Company, Abbott Laboratories, GlaxoSmithKline plc., Bayer AG, Novartis AG

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Acute Otitis Media (AOM)
4.2.2 Rising New Products Launches for Acute Otitis Media Treatment
4.3 Market Restraints
4.3.1 Stringent Guidelines for Approval of The Drug for The Acute Otitis Media Treatment Among The Children
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Drug Type
5.1.1 Antibiotics
5.1.2 Nonsteroidal anti-Inflammatory drug
5.1.3 Analgesic
5.1.4 Anaesthetic
5.2 By Formulation
5.2.1 Oral
5.2.2 Topical
5.3 By Distribution Channel
5.3.1 Hospital
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Pfizer, Inc.
6.1.2 Eli Lilly and Company
6.1.3 Abbott Laboratories
6.1.4 GlaxoSmithKline plc.
6.1.5 Bayer AG
6.1.6 Novartis AG
6.1.7 Pediapharm Inc.
6.1.8 Sanofi S.A.
6.1.9 Bristol Myers Squibb Company

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pfizer, Inc.
  • Eli Lilly and Company
  • Abbott Laboratories
  • GlaxoSmithKline plc.
  • Bayer AG
  • Novartis AG
  • Pediapharm Inc.
  • Sanofi S.A.
  • Bristol Myers Squibb Company